NCT05519397View on ClinicalTrials.gov

Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

October 1, 2022

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

Immune checkpoint measurement

Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9

Trial Locations (1)

34098

Istanbul Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Istanbul Training and Research Hospital

OTHER_GOV

NCT05519397 - Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy | Biotech Hunter | Biotech Hunter